Bert Vogelstein

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (35)

Supplemental Figure 6. Correlation between the cfDNA derived from colon epithelial cells, lung cells, and pancreatic cells, and the fraction of cfDNA derived from neoplastic colon epithelial cells, lung cells, or pancreatic cells.

Year:

2025

Supplemental Figure 5. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Moss et al. (43). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 25 tissue types that could be assessed.

Year:

2025

Supplementary Table 1. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Sun et al. (3) and Moss et al. (43) by QP and NNLS. NA, not available. Supplementary Table 2. Demographic, clinical, and plasma cfDNA data for the patients included in the study deconvoluted by Loyfer et al. (44) NA, not available.

Year:

2025

Supplementary Notes 1-5. Supplementary Note 1: Origins of cell-free DNA. Supplementary Note 2: Leukocyte Lysis. Supplementary Note 3: Reference datasets and deconvolution algorithms used to interpret whole genome bisulfite sequencing data. Supplementary Note 4: Turnover rates. Supplementary Note 5: Relationships between ctDNA and tissue specific cfDNA in cancer patients.

Year:

2025

Supplemental Figure 2. The concentration of plasma cfDNA in previous described patients with cancer according to stage. (A) The concentration of cfDNA in patients of all cancer types (9). The concentration of cfDNA in patients with Stage III cancers was significantly higher than that of patients with Stage I cancers (p

Year:

2025

Supplemental Figure 10. In silico mixing experiments (N = 10) of buffy coat bisulfite sequencing data with liver (A), lung (B), colon epithelial cell (C), and left atrium (D) bisulfite sequencing data deconvoluted using the Moss et al. (43) reference matrix and quadratic programming shows excellent agreement between predicted and actual fractional contribution.

Year:

2025

Supplemental Figure 4. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Sun et al. (3). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 12 tissue types that could be assessed.

Year:

2025

Supplementary Table S1: Cohorts for CSF-BAM components. Supplementary Table S2A: SafeBSeqS primer sequences. Supplementary Table S2B: SafeTseqS primer sequences. Supplementary Table S2C: Aneuploidy analysis primer sequences. Supplementary Table S2D: Mutation analysis primer sequences. Genomic coordinates refer to hg19. Supplementary Table S3: Summary of SafeBSeqS analysis in WBC control samples. Supplementary Table S4: Summary of CSF-BAM SafeBSeqS analysis in CSF. Supplementary Table S5: Summary of SafeTSeqS analysis in WBC control samples. Supplementary Table S6: Summary of CSF-BAM SafeTSeqS analysis in CSF. Supplementary Table S7: SafeBSeqS and SafeTSeqS analysis for CSF validation set 2. Supplementary Table S8: Summary of aneuploidy analysis in control samples. Supplementary Table S9: Summary of CSF-BAM aneuploidy analysis in CSF samples. Supplementary Table S10: Reproducibility of aneuploidy analysis. Supplementary Table S11: Comparison of aneuploidy analysis with CSF-BAM and Real-CSF. Supplementary Table S12: CSF-BAM mutation training set in non-cancer CSF samples. Supplementary Table S13: CSF-BAM mutation analysis in CSF samples. Supplementary Table S14: Demographic characteristics by sample. Supplementary Table S15: Diagnostic categories by sample. Supplementary Table S16: CSF-BAM results summary. Supplementary Table S17: CSF-BAM detection based on CSF reservoir abutment by sample. All samples with available clinical data are included. P-values were calculated by Fisher’s exact test. Supplementary Table S18A: TCR Clusters obtained via CSF-BAM. Supplementary Table S18B: TCR specificity annotation. Supplementary Table S19: CSF samples from patients with multiple sclerosis analyzed with SafeTSeqS and SafeBSeqS.

Year:

2025

Supplementary Figure S1. SafeBSeqS amplification. Supplementary Figure S2. SafeTSeqS amplification. Supplementary Figure S3. Aneuploidy reproducibility from two independent aliquots and libraries. Supplementary Figure S4. Metrics for targeted mutation panel. Supplementary Figure S5. Correlation of predicted aneuploidy neoplastic content to mutation neoplastic content. Supplementary Figure S6. A, TCR UIDs and B, BCR UIDS recovered for each CSF sample. Supplementary Figure S7. A, TCR clonality and B, BCR clonality for evaluable samples with total UIDs ≥20. Supplementary Figure S8. BCR clonality ROC and BCR IGHV4-34 gene segment usage. Supplementary Figure S9. Case reports demonstrating CSF-BAM clinical applicability.

Year:

2025

To explore how early cancers can be detected prior to clinical signs or symptoms, we assessed prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities study, including 26 participants diagnosed with cancer and 26 matched controls. At the index time point, 8 of these 52 participants scored positively with a multicancer early detection test. All eight participants were diagnosed with cancer within 4 months after blood collection. In six of these eight participants, we were able to assess an earlier plasma sample collected 3.1 to 3.5 years prior to clinical diagnosis. In four of these six participants, the same mutations detected by the multicancer early detection test could be identified but at 8.6- to 79-fold lower mutant allele fractions. These results demonstrate that it is possible to detect ctDNA more than 3 years prior to clinical diagnosis and provide benchmark sensitivities required for this purpose. Significance: Earlier detection is a promising strategy to reduce cancer mortality. For cancers of all stages, therapies are more effective with a lower disease burden. In this study, we demonstrate that ctDNA is detectable 3 years or more before cancer diagnosis and provide estimates for the sensitivity required to achieve such very early detection. See related commentary by Crisafulli et al., p. 1774

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (31)

Peter A. Calabresi

-

UNITED STATES
View details

Maria Popoli

Johns Hopkins University

UNITED STATES
View details

Jarushka Naidoo

Honorary Senior Lecturer

Royal College of Surgeons in Ireland

IRELAND
View details

Maximilian F Konig

Director, Cellular Therapy Program (Autoimmunity)

Johns Hopkins University School of Medicine

UNITED STATES
View details

Christopher Douville

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Anna E. Prizment

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Joshua Cohen

Dana-Farber Cancer Institute

UNITED STATES
View details

Kamel Lahouel

Assistant Professor

Translational Genomics Research Institute

UNITED STATES
View details

Shibin Zhou

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Kenneth Kinzler

Professor

Johns Hopkins University

UNITED STATES
View details

Elizabeth Platz

Professor

Johns Hopkins University

UNITED STATES
View details

Josef Coresh

Professor

Johns Hopkins University

UNITED STATES
View details

Chetan Bettegowda

Johns Hopkins University School of Medicine

UNITED STATES
View details

Haley Grant

Assistant Professor

University of Pittsburgh

UNITED STATES
View details

Cristian Tomasetti

Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Debraj Mukherjee

Faculty

Johns Hopkins University School of Medicine

UNITED STATES
View details

Carlos A Pardo

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Yuk Ming Dennis Lo

Li Ka Shing Professor of Medicine

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

David Kamson

Johns Hopkins University

UNITED STATES
View details

Corinne Joshu

Johns Hopkins University

UNITED STATES
View details

Eric Jackson

Associate Professor of Neurosurgery

Johns Hopkins University School of Medicine

UNITED STATES
View details

KC Allen Chan

Professor

The Chinese University of Hong Kong (CUHK)

HONG KONG
View details

Karisa Schreck

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Matthias Holdhoff

Johns Hopkins University School of Medicine

UNITED STATES
View details

Suman Paul

Johns Hopkins University

UNITED STATES
View details

Brenda Diergaarde

University of Pittsburgh

UNITED STATES
View details

Alireza Mansouri

Assistant Professor

Penn State

UNITED STATES
View details

George Jallo

Johns Hopkins University

UNITED STATES
View details

Cole Sterling

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Drew Pardoll

Professor

Johns Hopkins University

UNITED STATES
View details